Wyeth Paying $491M To End Criminal, Civil Rapamune Cases

Law360, Chicago (July 30, 2013, 5:44 PM EDT) -- Wyeth Pharmaceuticals Inc. has agreed to shell out $491 million to end a criminal action as well as civil False Claims Act cases alleging it illegally marketed its immunosuppressive drug Rapamune for unapproved uses, the U.S. Department of Justice said Tuesday.

Wyeth, which was acquired by Pfizer Inc. in 2009, also pled guilty to a criminal information alleging it misbranded the prescription drug in violation of the Federal Food, Drug and Cosmetic Act. Under that plea deal, which a federal court in Oklahoma has accepted, Wyeth...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.